While it is reasonable to first target cancer types such as breast cancer and lung cancer where there is both cancer and stroma expression of Enpp1, our data suggests that stromal Enpp1 is sufficient to limit adaptive immune control of colorectal tumors where Enpp1 is not present in the cancer cells. This evidence concerns the gene ENPP1 and breast carcinoma.